Emergent Biosolutions Inc (NYSE:EBS) Given Consensus Recommendation of “Buy” by Analysts

Shares of Emergent Biosolutions Inc (NYSE:EBS) have been given a consensus recommendation of “Buy” by the nine analysts that are currently covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $70.00.

A number of research firms have weighed in on EBS. Chardan Capital reaffirmed a “buy” rating and set a $71.00 price objective on shares of Emergent Biosolutions in a research report on Thursday, November 7th. Wells Fargo & Co reaffirmed a “buy” rating on shares of Emergent Biosolutions in a research report on Thursday, November 7th. Guggenheim began coverage on Emergent Biosolutions in a research report on Thursday, September 12th. They set a “buy” rating and a $65.00 price objective for the company. ValuEngine cut Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Thursday. Finally, TheStreet raised Emergent Biosolutions from a “c” rating to a “b” rating in a research report on Wednesday, November 6th.

Emergent Biosolutions stock opened at $54.71 on Thursday. Emergent Biosolutions has a twelve month low of $39.11 and a twelve month high of $73.89. The stock has a 50 day moving average of $54.25 and a two-hundred day moving average of $48.11. The company has a current ratio of 2.54, a quick ratio of 1.71 and a debt-to-equity ratio of 0.79. The stock has a market capitalization of $2.77 billion, a price-to-earnings ratio of 27.56, a PEG ratio of 0.89 and a beta of 1.55.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $1.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.63 by $0.58. Emergent Biosolutions had a return on equity of 10.05% and a net margin of 0.42%. The company had revenue of $311.80 million during the quarter, compared to analysts’ expectations of $289.16 million. During the same period last year, the firm earned $0.55 EPS. The firm’s revenue for the quarter was up 79.6% on a year-over-year basis. Equities analysts predict that Emergent Biosolutions will post 3.08 earnings per share for the current year.

In other news, Director Kathryn C. Zoon sold 1,509 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $56.12, for a total value of $84,685.08. Following the completion of the sale, the director now directly owns 21,494 shares of the company’s stock, valued at approximately $1,206,243.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kathryn C. Zoon sold 3,082 shares of the firm’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $54.15, for a total value of $166,890.30. Following the completion of the sale, the director now directly owns 18,412 shares of the company’s stock, valued at $997,009.80. The disclosure for this sale can be found here. 14.10% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently bought and sold shares of EBS. Private Capital Group LLC raised its holdings in Emergent Biosolutions by 11.1% during the second quarter. Private Capital Group LLC now owns 2,397 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 239 shares during the last quarter. Outlook Wealth Advisors LLC raised its holdings in Emergent Biosolutions by 4.4% during the third quarter. Outlook Wealth Advisors LLC now owns 5,739 shares of the biopharmaceutical company’s stock worth $300,000 after purchasing an additional 244 shares during the last quarter. Greenwood Capital Associates LLC raised its holdings in Emergent Biosolutions by 3.9% during the second quarter. Greenwood Capital Associates LLC now owns 7,737 shares of the biopharmaceutical company’s stock worth $374,000 after purchasing an additional 291 shares during the last quarter. Capital Asset Advisory Services LLC raised its holdings in Emergent Biosolutions by 5.1% during the third quarter. Capital Asset Advisory Services LLC now owns 6,629 shares of the biopharmaceutical company’s stock worth $347,000 after purchasing an additional 320 shares during the last quarter. Finally, Clarus Wealth Advisors raised its holdings in Emergent Biosolutions by 30.7% during the second quarter. Clarus Wealth Advisors now owns 2,114 shares of the biopharmaceutical company’s stock worth $102,000 after purchasing an additional 496 shares during the last quarter. 87.98% of the stock is owned by institutional investors and hedge funds.

About Emergent Biosolutions

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.

Read More: Stock Symbols and CUSIP Explained

Analyst Recommendations for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.